
Imvax Advances a New Approach to Personalized Cancer Immunotherapy
**Sponsored Content**
Learn more about Imvax’s Phase 2b trial studying a personalized, whole tumor-derived immunotherapy in newly diagnosed patients with glioblastoma.
What is your brain tumor story? Click here to share it. Your story matters.
Sign up for our bi-monthly email to get the latest news on treatments, support, and stories from the brain tumor community.
**Sponsored Content**
Learn more about Imvax’s Phase 2b trial studying a personalized, whole tumor-derived immunotherapy in newly diagnosed patients with glioblastoma.
On November 17, 2022, results from a phase 3 trial of DCVax-L, an immunotherapy for glioblastoma patients, were published in the Journal of the American Medical Association (JAMA) Oncology.